CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 54 enrolled
Drug / intervention
MTAdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06795282
NCT06795282N/ACompleted
CompareCT.gov

Effects of Three Different Root Canal Filling Materials Used in Single-Session Root Canal Treatment on Postoperative Pain: A Randomized Clinical Study

TC Erciyes University·observational·Posted Jan 28, 2025·Updated Jan 2, 2026

In Brief

An observational study evaluating MTA for Dental Pulp Disease and 2 related conditions. Completed, enrolled 54 participants across 1 site.

Detailed Summary

The aim of this study was to investigate the difference in postoperative pain caused by different root canal sealers in patients with irreversible pulpitis symptoms and no apical lesions.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDental Pulp Disease, Endodontically Treated Teeth, Endodontic Disease
CountriesTurkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedJan 28, 2025
Enrollment StartJan 30, 2025
Primary CompletionDec 1, 2025
Study CompletionDec 15, 2025
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 1.4 years ago

Interventions

MTAdrug

MTA is primarily composed of tricalcium silicate, dicalcium silicate, bismuth oxide (for radiopacity), and small amounts of calcium sulfate. MTA is highly biocompatible, making it suitable for use in the root canal system and areas in close contact with tissues.